Apr 15, 2020
FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer
Apr 09, 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Feb 10, 2020
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
Dec 02, 2019
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Nov 11, 2019
Global Urothelial Carcinoma Market Insights, Epidemiology and Market Forecasts Report 2019-2028
Sep 28, 2019
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
Sep 16, 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jun 04, 2019
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Jun 03, 2019
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
May 03, 2019
The Italian R&D Excellence at the American Urological Association's 2019 Annual Meeting
Apr 12, 2019
BALVERSA(TM) (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
Mar 28, 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Feb 11, 2019
Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium
Jan 23, 2019
Nucleix Announces Initial Positive Results in Detection of Upper Tract Urothelial Carcinoma With Its Bladder EpiCheck Urine Test
Oct 31, 2018
Worldwide Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report (2018-2023) by Treatment Class (Chemotherapy, Immunotherapy)
Oct 30, 2018
Urothelial Cancer Drugs Market Size Worth $3.6 Billion By 2023: Grand View Research, Inc.
Jun 03, 2018
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Jun 03, 2018
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
May 24, 2018
Cxbladder(TM) Monitor Demonstrates Clinical Utility In Patients Being Monitored For Recurrent Bladder Cancer (UC)